All patients | Women | Men | Pinteraction | ||||
---|---|---|---|---|---|---|---|
Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
DOACs vs Warfarin (ref.) | |||||||
Apixaban vs Warfarin | 0.79 (0.62–1.02) | 0.07 | 1.02 (0.69–1.50) | 0.92 | 0.62 (0.46–0.84) | 0.002 | 0.046 |
Dabigatran vs Warfarin | 0.69 (0.56–0.86) | < 0.001 | 0.69 (0.50–0.96) | 0.03 | 0.70 (0.53–0.92) | 0.01 | 0.99 |
Rivaroxaban vs Warfarin | 0.82 (0.64–1.04) | 0.1 | 0.98 (0.68–1.40) | 0.9 | 0.70 (0.51–0.97) | 0.03 | 0.18 |
Apixaban/ Rivaroxaban vs Warfarin | 0.80 (0.66–0.99) | 0.04 | 1.00 (0.73–1.37) | 0.99 | 0.66 (0.51–0.86) | 0.002 | 0.048 |
DOACs vs DOACs (ref.) | |||||||
Apixaban vs Dabigatran | 1.14 (0.90–1.46) | 0.28 | 1.47 (1.02–2.13) | 0.04 | 0.89 (0.66–1.21) | 0.46 | 0.04 |
Rivaroxaban vs Dabigatran | 1.18 (0.93–1.50) | 0.17 | 1.41 (1.00–1.99) | 0.05 | 1.01 (0.73–1.39) | 0.96 | 0.17 |
Rivaroxaban vs Apixaban | 1.03 (0.79–1.35) | 0.82 | 0.96 (0.64–1.43) | 0.83 | 1.13 (0.80–1.60) | 0.48 | 0.54 |
Apixaban/ Rivaroxaban vs Dabigatran | 1.16 (0.95–1.42) | 0.14 | 1.44 (1.07–1.94) | 0.02 | 0.95 (0.73–1.24) | 0.7 | 0.04 |